Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 13, No 4 (2020) The social-economic burden of spinal muscular atrophy in Russia Abstract  similar documents
A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina
"... social-economic burden of SMA in Russia was 2.37 billion RUR/year (2.38 million RUR/patient/year ..."
 
Vol 12, No 2 (2019) Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers Abstract  similar documents
E. V. Radchenko, A. S. Kolbin
"... Aim: to assess the socio-economic burden of smoking in the Russian Federation for 2017. Materials ..."
 
Vol 9, No 2 (2016) PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION Abstract  similar documents
T. V. Gaygolnik, I. V. Demko, E. N. Bochanova, A. Yu. Kraposhina, N. V. Gordeeva, I. A. Soloveva
"... Целью исследования было проведение анализа структуры и рациональности затрат на обеспечение ..."
 
Vol 7, No 3 (2014) THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva
"... of social and economic burden of disease) is one of the most widely used. Our objective was to analyze ..."
 
Vol 13, No 3 (2020) Economic burden of systemic sclerosis: systematic review Abstract  similar documents
D. L. Klabukova, V. S. Krysanova, T. N. Ermolaeva, M. V. Davydovskaya, K. A. Kokushkin
"... a high mortality rate. Treatment of its various complications imposes a great financial burden ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... Study objective: to perform assessment of the social and economic burden (analysis of the cost ..."
 
Vol 9, No 4 (2016) THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE Abstract  similar documents
G. E. Ulrikh, A. V. Rudakova
"... . Reducing the burden on the budget could be achieved under the assumption of equal efficacy of drugs ..."
 
Vol 10, No 2 (2017) COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA Abstract  similar documents
N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov
"... using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient ..."
 
Vol 6, No 1 (2013) PHARMACOECONOMIC STUDY OF SKIN TESTS IN THE DIAGNOSTICS OF TUBERCULOSIS INFECTION Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... were 122.687 RUR, 3.646.833 RUR and 551.150 RUR, for the estimated diagnostic schemes, respectively ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... – 470 120.40 RUR, which is 51% of the willingness-to-pay threshold in Russia. With the lowest ..."
 
Vol 13, No 4 (2020) Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy Abstract  similar documents
I. N. Dyakov, S. R. Varfolomeеva
"... the cost of surgical treatments by 31.7% or 56,486,07 RUR per patient per year. The application ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation Abstract  similar documents
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev
"... cells/µl, will increase the burden on the budget by 13.25% or by 83.2 million rubles. In a group of 594 ..."
 
Vol 10, No 4 (2017) PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... The aim – assess the clinical advantages and economic burden of various treatment strategies ..."
 
Vol 11, No 1 (2018) Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... budget and in relation to the social burdens; the appropriateness and effectiveness of  the present costs ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... and the social burdens; we also looked into the relevance and effectiveness of the current costs at various time ..."
 
Vol 12, No 2 (2019) Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria Abstract  similar documents
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... impact analysis showed that the reduction in the health budget burden would reach 29% or 34.3 million ..."
 
Vol 7, No 3 (2014) MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan
"... was possible in 2 cases. The total costs per cohort were 1.71 mln RUR. in case of TST testing (including ..."
 
Vol 7, No 1 (2014) ABC END VEN ANALYSYS OF COSTS FOR MEDICINE SAND MEDICAL TREATMENT COSTS PATIENT Abstract  similar documents
M. A. Shapovalova, L. R. Koretskaya
 
Vol 10, No 2 (2017) PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY Abstract  similar documents
A. V. Rudakova, S. A. Protsenko, I. A. Koroleva
"... исследования: оценка затрат на иммунотерапию во второй линии терапии НМРЛ. Материалы и методы. Прямые ..."
 
Vol 5, No 2 (2012) METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES Abstract  similar documents
R. I. Yagudina, I. V. Sorokovikov
"... фармакоэкономический анализ «затраты-полезность» (cost-utilityanalysis CUA) является третьим по ..."
 
Vol 5, No 3 (2012) COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES Abstract  similar documents
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova
"... , физиотерапия). Анализировались прямые затраты в течение 12 месяцев наблюдения пациентов. Показатели качества ..."
 
Vol 12, No 1 (2019) Individual cost accounting in the management of medical organizations Abstract  similar documents
I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali
"... планирование расходов и комплексная оптимизация процессов. Изучение затрат позволяет выработать правильную ..."
 
Vol 12, No 4 (2019) Crucial areas of the economic analysis of public cancer care Abstract  similar documents
D. A. Andreev, K. I. Polyakova, A. A. Zavyalov, T. N. Ermolaeva, A. G. Fisun, A. D. Ermolaeva, V. A. Dubovtseva, T. E. Maksimova
"... направлений для анализа экономических затрат, влияющих на эффективность оказания медицинских услуг пациентам с ..."
 
Vol 7, No 2 (2014) THE ANALYSIS OF THE EFFECTIVENESS OF THROMBOPROPHYLAXIS AMONG PREGNANT WOMEN WITH MESENCHYMAL DYSPLASIA Abstract  similar documents
E. G. Kudinova, A. P. Momot, N. V. Trukhacheva
"... осложнений и, следовательно, уменьшаются финансовые затраты. ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER Abstract  similar documents
A. U. Kulikov
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... инфузионной терапии: Реамберин, раствор Рингера, Плазма-Лит и Стерофундин. Проведены анализ затрат, анализ ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION Abstract  similar documents
A. Yu. Kulikov, I. Yu. Zinchuk
"... , ФЭК-анализ проводился с учетом двух сценариев – «минимизация затрат» и «затраты-эффективность». В ходе ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... в статье представлены результаты расчета необходимых финансовых затрат на лекарственное ..."
 
Vol 8, No 2 (2015) REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS Abstract  similar documents
Natalia Nikolayevna Sisigina, Vitalii Vladimirovich Omel'yanovskii, Nikolay Alexandrovich Avxentyev
"... В статье проводится обзор международного опыта использования механизма разделения затрат в целях ..."
 
Vol 9, No 2 (2016) EVALUATION OF RATIONALITY OF EXPENSES ON TREATMENT OF SEVERE COMMUNITY-ACQUIRES PNEUMONIA IN MULTI-PROFILE HOSPITAL Abstract  similar documents
I. V. Demko, N. V. Gordeeva, E. N. Bochanova, N. I. Golovina, A. Yu. Kraposhina, I. A. Soloveva, E. A. Sobko, T. V. Gaygolnik, S. V. Chubarova
"... Цель — изучить рациональность финансовых затрат на лечение пациентов с тяжелым течением пневмонии ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... затрат и эффективности сравниваемых курсов терапии острого обструктивного бронхита был применен метод ..."
 
Vol 11, No 2 (2018) Introduction of medical products into healthcare practice and costs reimbursement: European experience Abstract  similar documents
V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii
 
Vol 11, No 4 (2018) Costs of pharmacotherapy in pediatric patients with community-acquired pneumonia: mathematical and statistical analysis Abstract  similar documents
I. A. Narkevich, O. D. Nemyatyh, D. D. Siukaeva, I. V. Pavlushkov, D. O. Ivanov, Ya. V. Panyutina
"... формирования затрат на фармакотерапию у стационарных больных на примере пациентов детского возраста с диагнозом ..."
 
Vol 12, No 4 (2019) Clinical and economic analysis of drug costs in a general hospital in 2014-2018 Abstract  similar documents
A. T. Burbello, A. S. Fedorenko, E. L. Latariya, M. V. Pokladova, K. A. Zagorodnikova
 
Vol 13, No 2 (2020) Prognosis of the influence of direct oral anticoagulants on the direct medical expenses in patients with atrial fibrillation Abstract  similar documents
S. V. Malchikova, A. N. Korobeinikova, N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva
"... «затраты-эффективность»; анализ «влияния на бюджет»; анализ  «упущенных возможностей». Результаты ..."
 
Vol 13, No 4 (2020) Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system Abstract  similar documents
T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky
"... «затраты-эффективность»). Однако в РФ на данный момент референтное значение инкрементального показателя ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
"... Федерации.  Результаты: Коэффициенты «затраты-эффективность» при использовании Ревлимида во второй линии ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... непрозрачный, и в целом затраты на них оказываются очень высокими. В связи с этим для принятия обоснованных ..."
 
Vol 8, No 2 (2015) CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA Abstract  similar documents
Elena Albertovna Sobko, Natalya Vladimirovna Gordeeva, Angelina Yurievna Kraposhina, Irina Anatolyevna Soloveva, Svetlana Vladimirovna Chubarova, Olga Petrovna Ishenko, Irina Vladimirovna Demko, Maria Michailovna Loktionova
"... был использован коэффициент «затраты-эффективность». Результаты. Проведенный анализ показал, что ..."
 
Vol 12, No 4 (2019) Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis Abstract  similar documents
I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva
"... коленного сустава II стадии по классификации Kellgren & Lawrence. Применен анализ эффективности затрат на ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... полезности затрат (CUA), оценки влияния на бюджет. Результаты. Применение дапаглифлозина в качестве ..."
 
Vol 5, No 2 (2012) COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS Abstract  similar documents
A. V. Rudakova
 
Vol 8, No 4 (2015) PLANNING OF EXTENT AND FINANCIAL EXPENSES FOR DELIVERY OF HEALTH CARE IN HOSPITALS AT THE FEDERAL AND REGIONAL LEVELS Abstract  similar documents
M. V. Sura
"... Введение. Планирование объемов и финансовых затрат на оказание медицинской помощи в стационарных ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... миелолейкоз (ХМЛ) в хронической фазе (ХФ). Результаты анализа «затраты-эффективность», выполненного с ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS Abstract  similar documents
M. V. Protsenko
"... «минимизация затрат», анализа «затраты – полезность», анализа «порога «готовности платить» и анализа «влияния ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... вариантом отсутствия применения данного препарата. На основании результатов анализа «затраты-эффективность ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... протяжении 19 лет применение нилотиниба является доминантным, с точки зрения анализа «затраты-полезность», и ..."
 
Vol 5, No 1 (2012) PHARMACOECONOMIC EVALUATION OF THE PROPHYLAXIS OF POSTSURGICAL INFECTIOUS INFLAMMATORY COMPLICATIONS OF COMBINED ANTIBIOTIC DRUGS AND CORTICOSTEROIDS IN OPHTHALMIC PRACTICE IN RUSSIAN FEDERATION Abstract  similar documents
V. G. Serpik, R. I. Yagudina
"... Комбинил-Дуо по коэффициенту «затраты-эффективность», в качестве которого была использована стоимость ..."
 
Vol 6, No 2 (2013) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS Abstract  similar documents
A. Yu. Kulikov, V. G. Serpik
"... анализа «затраты-эффективность». Результаты показали, что препарат Азопт обладает преимуществом над ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... , моделирование. Метод фармакоэкономического анализа – «затраты-полезность». Горизонт моделирования – 10 лет ..."
 
1 - 50 of 133 Items 1 2 3 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)